SG11202003479TA - Fully-human post-translationally modified antibody therapeutics - Google Patents
Fully-human post-translationally modified antibody therapeuticsInfo
- Publication number
- SG11202003479TA SG11202003479TA SG11202003479TA SG11202003479TA SG11202003479TA SG 11202003479T A SG11202003479T A SG 11202003479TA SG 11202003479T A SG11202003479T A SG 11202003479TA SG 11202003479T A SG11202003479T A SG 11202003479TA SG 11202003479T A SG11202003479T A SG 11202003479TA
- Authority
- SG
- Singapore
- Prior art keywords
- fully
- modified antibody
- translationally modified
- antibody therapeutics
- human post
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574106P | 2017-10-18 | 2017-10-18 | |
US201762609750P | 2017-12-22 | 2017-12-22 | |
US201862700124P | 2018-07-18 | 2018-07-18 | |
PCT/US2018/056346 WO2019079496A2 (fr) | 2017-10-18 | 2018-10-17 | Agents thérapeutiques à base d'anticorps entièrement humains à modification post-traductionnelle |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003479TA true SG11202003479TA (en) | 2020-05-28 |
Family
ID=64110209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003479TA SG11202003479TA (en) | 2017-10-18 | 2018-10-17 | Fully-human post-translationally modified antibody therapeutics |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200093939A1 (fr) |
EP (2) | EP3697815A2 (fr) |
JP (2) | JP2021501196A (fr) |
KR (1) | KR20200067195A (fr) |
CN (1) | CN111727201A (fr) |
AU (1) | AU2018350992A1 (fr) |
BR (1) | BR112020007405A2 (fr) |
CA (1) | CA3079568A1 (fr) |
IL (1) | IL273745A (fr) |
MX (1) | MX2020003888A (fr) |
SG (1) | SG11202003479TA (fr) |
WO (1) | WO2019079496A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
US20210071149A1 (en) | 2017-12-19 | 2021-03-11 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
AU2019221642A1 (en) * | 2018-02-14 | 2020-07-09 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for antibody and fusion protein production |
CN112351787A (zh) * | 2018-05-04 | 2021-02-09 | 俄勒冈健康与科学大学 | 人抗aav2衣壳多克隆抗体表位 |
CN113924115A (zh) | 2019-01-31 | 2022-01-11 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
US20220339270A1 (en) * | 2019-04-29 | 2022-10-27 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tauopathy |
CN114207135A (zh) * | 2019-06-11 | 2022-03-18 | 夏尔人类遗传性治疗公司 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
WO2021050666A1 (fr) * | 2019-09-11 | 2021-03-18 | Aav Gene Therapeutics, Inc. | Aav-zyme et utilisation pour la thérapie de remplacement de perfusion |
WO2021169167A1 (fr) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Méthode de traitement d'infections à coronavirus |
SE544000C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein |
SE544001C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody |
EP4182691A2 (fr) * | 2020-07-17 | 2023-05-24 | Icahn School of Medicine at Mount Sinai | Biomarqueurs et classificateur du psoriasis et méthodes de traitement |
EP4213890A1 (fr) * | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Lanadelumab vectorisé et administration de celui-ci |
WO2022094157A1 (fr) * | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Anticorps vectorisés anti-cgrp et anti-récepteur de cgrp et leur administration |
WO2022094255A2 (fr) * | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Anticorps de facteur xii vectorisés et leur administration |
TW202241943A (zh) * | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau特異性抗體基因療法組合物、方法及其用途 |
WO2022164288A1 (fr) | 2021-01-29 | 2022-08-04 | 한국과학기술원 | Molécule de fusion présentant une activité induisant une phagocytose non inflammatoire |
MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
CN113651882B (zh) * | 2021-08-04 | 2022-06-10 | 广州呼研所医药科技有限公司 | 人源化抗HAdV-B3单克隆中和抗体、制备方法及其应用 |
CN115772544B (zh) * | 2021-09-06 | 2024-04-26 | 合肥星眸生物科技有限公司 | 抗vegf-a和ang-2的aav载体 |
CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
WO2023213779A1 (fr) * | 2022-05-02 | 2023-11-09 | Novo Nordisk A/S | Nouveaux anticorps anti-angptl3 appropriés pour des compositions à concentration élevée et administration sous-cutanée |
WO2023215807A1 (fr) * | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | INHIBITEURS VECTORISÉS ANTI-TNF-α POUR INDICATIONS OCULAIRES |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69435260D1 (de) | 1993-02-12 | 2010-02-11 | Univ R | Regulierte transkription von zielgerichteten genen und andere biologische ereignisse |
CA2209183A1 (fr) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Proteines chimeres de liaison d'adn |
WO1996041865A1 (fr) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Regulation d'evenements biologiques fondee sur la rapamycine |
CA2300376A1 (fr) | 1997-08-26 | 1999-03-04 | Ariad Gene Therapeutics, Inc. | Proteines de fusion a domaine de dimerisation, de trimerisation ou de tetramerisation, et a domaine additionnel d'activation de transcription heterologue, d'inhibition de transcription, de liaison d'adn ou de liaison de ligand |
AU752129B2 (en) | 1997-08-27 | 2002-09-05 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
WO1999036553A2 (fr) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation de phenomenes biologiques au moyen de proteines chimeres multimeres |
WO1999041258A1 (fr) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Agents de dimerisation, production et utilisation |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
CA2756866C (fr) | 2001-11-13 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Methode de detection et/ou d'identification de sequences de virus associes aux adenovirus (aav) et d'isolation de nouvelles sequences ainsi identifiees |
EP2359869B1 (fr) | 2001-12-17 | 2018-12-26 | The Trustees Of The University Of Pennsylvania | Séquences de virus adéno-associés de sérotype 8 , vecteurs les contenant et leurs utilisations |
PT2573170T (pt) * | 2001-12-17 | 2018-03-26 | Univ Pennsylvania | Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações |
KR20070086866A (ko) * | 2003-02-13 | 2007-08-27 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 i 수용체 항체의 용도 |
PL2292780T3 (pl) | 2003-09-30 | 2018-05-30 | The Trustees Of The University Of Pennsylvania | Klady wirusów związanych z adenowirusami (AAV), sekwencje, wektory je zawierające i ich zastosowania |
ES2580044T3 (es) | 2005-04-07 | 2016-08-18 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
WO2006132118A1 (fr) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | Appareil de compensation d’erreur d’amplitude et appareil de compensation d’erreur d’orthogonalité |
FI20075278A0 (fi) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
KR20130040844A (ko) * | 2010-03-29 | 2013-04-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 약학적으로 유발된 전이유전자 제거 시스템 |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
WO2012057363A1 (fr) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales |
US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
RS60207B1 (sr) | 2011-04-22 | 2020-06-30 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
TWI496886B (zh) * | 2011-06-24 | 2015-08-21 | Taipei Veteran General Hospital | 提升感染性與惡性疾病之治療之免疫反應 |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
JP6385920B2 (ja) | 2012-05-09 | 2018-09-05 | オレゴン ヘルス アンド サイエンス ユニバーシティー | アデノ随伴ウイルスプラスミド及びベクター |
EP2970946A4 (fr) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | Vecteurs viraux adéno-associés et méthodes d'utilisation associées |
CA3208188A1 (fr) * | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anticorps anti-kallicreine plasmatique |
US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
EP3744730A1 (fr) | 2013-10-11 | 2020-12-02 | Massachusetts Eye & Ear Infirmary | Méthodes de prédiction de séquences virales ancestrales et leurs utilisations |
AU2015209481C1 (en) * | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
WO2015164757A1 (fr) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Procedes de cartographie d'epitopes d'anticorps de neutralisation virale |
EP3134115A4 (fr) * | 2014-04-25 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Procédés et compositions pour le traitement du cancer du sein métastatique et d'autres cancers dans le cerveau |
CA2972800A1 (fr) * | 2015-01-02 | 2016-07-07 | Dyax Corp. | Anticorps bispecifiques agissant a l'encontre la kallicreine plasmatique et du facteur xii |
US11535665B2 (en) * | 2015-05-13 | 2022-12-27 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
WO2017011773A2 (fr) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Acides nucléiques à codons optimisés codant des anticorps |
IL292830B2 (en) * | 2015-09-28 | 2023-06-01 | Univ Florida | Methods and compositions for stealth virus antibody vectors |
US11135313B2 (en) * | 2015-10-28 | 2021-10-05 | The Trustees Of The University Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
IL259595B2 (en) * | 2015-12-01 | 2024-01-01 | Spark Therapeutics Inc | Gradual methods for the production of a recombinant adenovirus (AAV) vector in a serum-free suspension cell culture system suitable for clinical use |
WO2018075798A1 (fr) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Capsides d'aav modifiées et leurs utilisations |
-
2018
- 2018-10-17 MX MX2020003888A patent/MX2020003888A/es unknown
- 2018-10-17 BR BR112020007405-5A patent/BR112020007405A2/pt unknown
- 2018-10-17 AU AU2018350992A patent/AU2018350992A1/en active Pending
- 2018-10-17 KR KR1020207014076A patent/KR20200067195A/ko not_active Application Discontinuation
- 2018-10-17 EP EP18797410.0A patent/EP3697815A2/fr active Pending
- 2018-10-17 SG SG11202003479TA patent/SG11202003479TA/en unknown
- 2018-10-17 CA CA3079568A patent/CA3079568A1/fr active Pending
- 2018-10-17 EP EP23200645.2A patent/EP4317185A3/fr active Pending
- 2018-10-17 CN CN201880079166.3A patent/CN111727201A/zh active Pending
- 2018-10-17 WO PCT/US2018/056346 patent/WO2019079496A2/fr unknown
- 2018-10-17 JP JP2020542540A patent/JP2021501196A/ja active Pending
-
2019
- 2019-12-06 US US16/706,065 patent/US20200093939A1/en active Pending
-
2020
- 2020-04-01 IL IL273745A patent/IL273745A/en unknown
-
2023
- 2023-09-29 JP JP2023170015A patent/JP2024009845A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019079496A2 (fr) | 2019-04-25 |
AU2018350992A1 (en) | 2020-05-21 |
EP3697815A2 (fr) | 2020-08-26 |
IL273745A (en) | 2020-05-31 |
JP2021501196A (ja) | 2021-01-14 |
JP2024009845A (ja) | 2024-01-23 |
EP4317185A2 (fr) | 2024-02-07 |
EP4317185A3 (fr) | 2024-04-17 |
CN111727201A (zh) | 2020-09-29 |
WO2019079496A3 (fr) | 2019-06-13 |
KR20200067195A (ko) | 2020-06-11 |
CA3079568A1 (fr) | 2019-04-25 |
BR112020007405A2 (pt) | 2020-12-08 |
MX2020003888A (es) | 2020-11-06 |
US20200093939A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273745A (en) | Biased antibody therapy after full-human translation | |
IL287414A (en) | Antibody drugs are processed after fully human translation | |
IL287958A (en) | A healing antibody that binds cd47 | |
IL254260A0 (en) | A healing antibody that binds tim3 | |
ZA201803874B (en) | Humanized anti-cd73 antibodies | |
IL267797A (en) | Anti-gpc3 antibody | |
IL254088A0 (en) | Cure using cd137 binding antibody | |
EP3325009A4 (fr) | Anticorps thérapeutiques qui se lient à lag3 | |
GB201709808D0 (en) | Antibodies | |
HK1258375A1 (zh) | 人源化抗-cll-1抗體 | |
EP3280443A4 (fr) | Agents thérapeutiques de type anticorps se liant à cd38 | |
IL256579A (en) | Human antibodies | |
EP3175242A4 (fr) | Quantification d'agents thérapeutiques de type anticorps monoclonaux par lc-ms/ms | |
GB201707561D0 (en) | GARP-TGF-beta antibodies | |
EP3280442A4 (fr) | Agents thérapeutiques de type anticorps se liant à cd123 | |
EP3131580A4 (fr) | Agents thérapeutiques de type anticorps se liant à cd147 | |
EP3268039A4 (fr) | Agents thérapeutiques de type anticorps liant psma | |
IL273529A (en) | Anti-PACAP antibody | |
PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
SI3456736T1 (sl) | Variante protitelesa | |
IL273351A (en) | antibody variants | |
IL272951A (en) | antibody variants | |
GB201711785D0 (en) | Antibodies | |
EP3362093A4 (fr) | Anticorps monoclonaux neutralisant l'héparanase | |
GB201511196D0 (en) | Monoclonal antibodies |